Prognostic Value of CD318 in AML at Assiut University Hospital.

Prognostic Value of CD318 in Acute Myeloid Leukemia Patients at Assiut University Hospital

Sponsors

Lead Sponsor: Shimaa Arafa Ibrahim

Source Assiut University
Brief Summary

We will focus on the prognostic value of CD318 in acute myeloid leukemia patients at Assiut University Hospital

Detailed Description

Acute myeloid leukemia (AML) is a disease with high mortality and variable prognosis . It remains a disease with a highly variable outcome depending on the exact footprint of the AML .Although many patients with AML have a response to induction therapy ,refractory disease is common and relapse represents the major cause of treatment failure .In 2016 the World Heath Organization published revisions to classification of Myeloid Neoplasms and Acute leukemias .Well-established prognostic factors are cytogenetic aberrations such as t(8;21), inv(16), and t(15;17) as well as mutated IDH1/2, NPM1, and FLT3 genes but only few markers can specifically predict the outcome after HSCT .Immunophenotyping via flowcytometry comprises an additional fast technique to predict outcome in AML, although only few markers are yet established as prognostic factors in clinical routine diagnosis, despite the fact that new and rapidly available markers are needed to improve the treatment decisions in AML patients. This is even more since starting therapy in AML patients must be initiated immediately after diagnosis . Overall mortality from AML is high and treatment should be initiated within hours after first diagnosis . In hematopoietic cells,CD318 has been identified as stem cell marker for both benign and malignant progenitor cells. CD318+ bone marrow or cord blood-derived cells have been shown to be capable to initiate multi-lineage hematopoiesis in vitro and in vivo .CD318 (CUB domain containing protein-1, CDCP1) is a highly glycosylated single pass transmembrane protein express endomesenchymal and neural stem cells and fibroblasts and hematopoietic.Overexpression of CD318 has been recently correlated with poor overall survival(OS) in colonic ,breast ,renal, hepatocellular ,and pancreatic Carcinoma.possibly due to its role in metastasis formation via interaction with integrins and anti-apoptotic signaling via Akt. Of AML blasts, pronounced CD318 expression has been observed on the immature CD34+CD133+ leukemic cells subset implicated to be enriched for leukemic stem. However, the impact of CD318 on survival in hematological malignancies has so far not been analyzed. Study done by Jonas S et al showed 57% of AML patients expressed relevant CD318 levels and a significant correlation of CD 318 surface levels with prognosis was observed . In our study investigators will use flowcytometry to detect CD318 on AML blasts and correlate it with disease course and outcome.

Overall Status Not yet recruiting
Start Date March 2021
Completion Date March 2023
Primary Completion Date September 2022
Study Type Observational
Primary Outcome
Measure Time Frame
Prognosis of CD318 in AML Throughout study completion, average of one year
Enrollment 100
Condition
Intervention

Intervention Type: Diagnostic Test

Intervention Name: CD318

Description: Flowcytometric marker

Eligibility

Sampling Method: Non-Probability Sample

Criteria:

Inclusion Criteria: 1. newly diagnosed AML patients 2. Age more than 18 years 3. Patients not starting chemotherapy yet 4. Primary AML 5. Secondary AML on top of MDS or myeloproliverative noeplasms Exclusion Criteria: 1. Refractory AML patients 2. Relapsed AML patients

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Verification Date

January 2021

Responsible Party

Type: Sponsor-Investigator

Investigator Affiliation: Assiut University

Investigator Full Name: Shimaa Arafa Ibrahim

Investigator Title: Assistant lecturer

Has Expanded Access No
Condition Browse
Study Design Info

Observational Model: Cohort

Time Perspective: Prospective

Source: ClinicalTrials.gov